Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and acknowledged ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Simulations Plus, Inc. regarding possible violations of federal securities laws, particularly related to alleged misrepresentations and omissions by the company and its executives [1] Company Background - Simulations Plus is a software company that serves the pharmaceutical, biotechnology, and chemical industries [3] - In June 2024, the company acquired Pro-ficiency Holdings, Inc., claiming this acquisition would double its total addressable market and serve as a key driver of growth [3] Recent Developments - On June 11, 2025, Simulations Plus announced disappointing preliminary results for Q3 2025, attributing the downturn to "market uncertainties," which led to a stock price drop of over 24%, from $26.44 to $20.05 per share [4] - Following this, on July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed its auditor, Grant Thornton LLP, which raised concerns about unresolved issues with segment reporting and internal controls [4] - The dismissal of the auditor and the acknowledgment of unresolved issues caused the stock to fall nearly 26%, from $17.47 to $12.97 per share [4]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings and subsequent financial reporting challenges [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings in June 2024, aiming to enhance its market reach and sales [2]. Group 2: Financial Reporting Issues - Simulations Plus claimed that the integration of Pro-ficiency would double its total addressable market and significantly boost sales, but it appears the integration was not successful and internal controls were ineffective [3]. - The company reported disappointing preliminary financial results for Q3 2025, citing market uncertainties, which led to a significant stock price drop of over 24% from $26.44 to $20.05 per share [4]. - A $77.2 million charge related to prior acquisitions was reported in Q3 2025, alongside the dismissal of its auditor Grant Thornton, which raised concerns about the company's internal controls and segment reporting [5]. Group 3: Stock Performance - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26%, from $17.47 to $12.97 per share [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings and subsequent financial reporting problems [1][2][3]. Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that there were struggles with the integration of Pro-ficiency and deficiencies in internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39 per share, a decline of over 24%, from $26.44 to $20.05 [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50 per share, nearly 26%, from $17.47 to $12.97 [5]. Auditor Dismissal - The dismissal of Grant Thornton was linked to unresolved issues regarding segment reporting and internal controls, which the auditor communicated to management and the Audit Committee [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls over financial reporting, which appears to be misleading as the company struggled with integration and lacked effective controls [3] - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, but shortly after, on June 11, 2025, it announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4] - Following the announcement, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4] - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the impairment charge and auditor dismissal [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to enhance its market reach and sales [2]. Group 2: Financial Reporting Issues - Simulations Plus claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears the integration was unsuccessful and internal controls were ineffective [3]. - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, which later raised concerns about the company's financial reporting [4][5]. Group 3: Stock Performance and Market Reaction - Following the announcement of disappointing preliminary financial results for Q3 2025 on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and acknowledged ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Group 3: Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to enhance its market reach and sales [2][3]. Group 2: Financial Reporting Issues - The company claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears that the integration was not successful and internal controls were ineffective [3]. - On April 15, 2025, Simulations Plus appointed Grant Thornton LLP as its new auditor, but shortly after, it reported disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4]. Group 3: Stock Performance - Following the announcement of disappointing financial results on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, which raised concerns about its internal controls and financial reporting [5]. - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the news of the impairment charge and auditor dismissal [5].